李兰娟：国家传染病重点学科带头人
李兰娟，中国传染病学专家，国家卫生健康委高级别专家组成员，中国工程院院士。曾承担SARS、手足口病、地震灾后防疫、甲型H1N1等传染病诊治研究任务，尤其在防控人感染H7N9禽流感救治研究中取得众多原创性成果，为中国传染病诊治做出了重大贡献。
在新冠肺炎疫情蔓延之际， 73岁的李兰娟率医疗队抵达武汉。在收治危重患者的定点医院，李兰娟不分昼夜地工作，向公众普及病毒知识、与医护人员商讨诊疗方案，每天只睡3个小时。在到达武汉后的第3天，李兰娟院士团队发布了重大研究成果，称阿比朵尔、达芦那韦两款药物能够有效抑制新型冠状病毒。随后，阿比朵尔列入《新型冠状病毒肺炎诊疗方案（试行第六版）》。
Li Lanjuan: Pioneer of Epidemiology
Li Lanjuan is a Chinese epidemiologist, a member of the High-level Expert Group of the NHC, and an academician of the Chinese Academy of Engineering. She has undertaken the tasks of diagnosis, treatment and research for infectious diseases such as the SARS, the hand-foot-and-mouth disease, post-quake epidemics and the H1N1 flu virus. She has made many groundbreaking achievements in the prevention and control of the H7N9 flu virus, and has contributed greatly to the diagnosis and treatment of infectious diseases in China.
Amid the outbreak of the novel coronavirus, the 73-year-old Li Lanjuan led a medical team to Wuhan and worked day and night at the designated hospitals for treating severe cases. She educated the public about the virus, discussed the guidelines for diagnosis and treatment with other medical workers, and slept only three hours a day.
Three days after arriving in Wuhan, Li's team announced an important research achievement, indicating that Arbidol and Darunavir could effectively curb the virus. Arbidol was later added in the Guidelines on the Novel Coronavirus-Infected Pneumonia Diagnosis and Treatment (Provisional 6th Edition).
